Literature DB >> 10978353

Recurrent germline mutation in MSH2 arises frequently de novo.

D C Desai1, J C Lockman, R B Chadwick, X Gao, A Percesepe, D G Evans, M Miyaki, S T Yuen, P Radice, E R Maher, F A Wright, A de La Chapelle.   

Abstract

INTRODUCTION: An intronic germline mutation in the MSH2 gene, A-->T at nt942+3, interferes with the exon 5 donor splicing mechanism leading to a mRNA lacking exon 5. This mutation causes typical hereditary non-polyposis colorectal cancer (HNPCC) and has been observed in numerous probands and families world wide. Recurrent mutations either arise repeatedly de novo or emanate from ancestral founding mutational events. The A-->T mutation had previously been shown to be enriched in the population of Newfoundland where most families shared a founder mutation. In contrast, in England, haplotypes failed to suggest a founder effect. If the absence of a founder effect could be proven world wide, the frequent de novo occurrence of the mutation would constitute an unexplored predisposition.
METHODS: We studied 10 families from England, Italy, Hong Kong, and Japan with a battery of intragenic and flanking polymorphic single nucleotide and microsatellite markers.
RESULTS: Haplotype sharing was not apparent, even within the European and Asian kindreds. Our marker panel was sufficient to detect a major mutation arising within the past several thousand generations. DISCUSSION: As a more ancient founder is implausible, we conclude that the A-->T mutation at nt942+3 of MSH2 occurs de novo with a relatively high frequency. We hypothesise that it arises as a consequence of misalignment at replication or recombination caused by a repeat of 26 adenines, of which the mutated A is the first. It is by far the most common recurrent de novo germline mutation yet to be detected in a human mismatch repair gene, accounting for 11% of all known pathogenic MSH2 mutations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10978353      PMCID: PMC1734701          DOI: 10.1136/jmg.37.9.646

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  32 in total

Review 1.  Genetic susceptibility to non-polyposis colorectal cancer.

Authors:  H T Lynch; A de la Chapelle
Journal:  J Med Genet       Date:  1999-11       Impact factor: 6.318

2.  Genetic mapping of a locus predisposing to human colorectal cancer.

Authors:  P Peltomäki; L A Aaltonen; P Sistonen; L Pylkkänen; J P Mecklin; H Järvinen; J S Green; J R Jass; J L Weber; F S Leach
Journal:  Science       Date:  1993-05-07       Impact factor: 47.728

3.  The origin of the major cystic fibrosis mutation (delta F508) in European populations.

Authors:  N Morral; J Bertranpetit; X Estivill; V Nunes; T Casals; J Giménez; A Reis; R Varon-Mateeva; M Macek; L Kalaydjieva
Journal:  Nat Genet       Date:  1994-06       Impact factor: 38.330

4.  hMSH2 mutations in hereditary nonpolyposis colorectal cancer kindreds.

Authors:  B Liu; R E Parsons; S R Hamilton; G M Petersen; H T Lynch; P Watson; S Markowitz; J K Willson; J Green; A de la Chapelle
Journal:  Cancer Res       Date:  1994-09-01       Impact factor: 12.701

5.  Antenatal diagnosis of sickle-cell anaemia by D.N.A. analysis of amniotic-fluid cells.

Authors:  Y W Kan; A M Dozy
Journal:  Lancet       Date:  1978-10-28       Impact factor: 79.321

6.  BAT-26 and BAT-40 instability in colorectal adenomas and carcinomas and germline polymorphisms.

Authors:  W S Samowitz; M L Slattery; J D Potter; M F Leppert
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

7.  Detection of mutations in mismatch repair genes in Portuguese families with hereditary non-polyposis colorectal cancer (HNPCC) by a multi-method approach.

Authors:  P Fidalgo; M R Almeida; S West; C Gaspar; L Maia; J Wijnen; C Albuquerque; A Curtis; M Cravo; R Fodde; C N Leitao; J Burn
Journal:  Eur J Hum Genet       Date:  2000-01       Impact factor: 4.246

8.  Linkage disequilibrium mapping in isolated founder populations: diastrophic dysplasia in Finland.

Authors:  J Hästbacka; A de la Chapelle; I Kaitila; P Sistonen; A Weaver; E Lander
Journal:  Nat Genet       Date:  1992-11       Impact factor: 38.330

9.  Haplotype relative risks: an easy reliable way to construct a proper control sample for risk calculations.

Authors:  C T Falk; P Rubinstein
Journal:  Ann Hum Genet       Date:  1987-07       Impact factor: 1.670

10.  Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer.

Authors:  F S Leach; N C Nicolaides; N Papadopoulos; B Liu; J Jen; R Parsons; P Peltomäki; P Sistonen; L A Aaltonen; M Nyström-Lahti
Journal:  Cell       Date:  1993-12-17       Impact factor: 41.582

View more
  34 in total

1.  Determining the frequency of de novo germline mutations in DNA mismatch repair genes.

Authors:  Aung Ko Win; Mark A Jenkins; Daniel D Buchanan; Mark Clendenning; Joanne P Young; Graham G Giles; Jack Goldblatt; Barbara A Leggett; John L Hopper; Stephen N Thibodeau; Noralane M Lindor
Journal:  J Med Genet       Date:  2011-06-02       Impact factor: 6.318

2.  Diagnosing Lynch syndrome: is the answer in the mouth?

Authors:  H K Roy; H T Lynch
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

3.  A unique MSH2 exon 8 deletion accounts for a major portion of all mismatch repair gene mutations in Lynch syndrome families of Sardinian origin.

Authors:  Iolanda Borelli; Marco A Barberis; Francesca Spina; Guido C Casalis Cavalchini; Caterina Vivanet; Luisa Balestrino; Monica Micheletti; Anna Allavena; Paola Sala; Carlo Carcassi; Barbara Pasini
Journal:  Eur J Hum Genet       Date:  2012-07-11       Impact factor: 4.246

4.  Identification and surveillance of 19 Lynch syndrome families in southern Italy: report of six novel germline mutations and a common founder mutation.

Authors:  Patrizia Lastella; Margherita Patruno; Giovanna Forte; Alba Montanaro; Carmela Di Gregorio; Carlo Sabbà; Patrizia Suppressa; Adalgisa Piepoli; Anna Panza; Angelo Andriulli; Nicoletta Resta; Alessandro Stella
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.375

5.  Feasibility of screening for Lynch syndrome among patients with colorectal cancer.

Authors:  Heather Hampel; Wendy L Frankel; Edward Martin; Mark Arnold; Karamjit Khanduja; Philip Kuebler; Mark Clendenning; Kaisa Sotamaa; Thomas Prior; Judith A Westman; Jenny Panescu; Dan Fix; Janet Lockman; Jennifer LaJeunesse; Ilene Comeras; Albert de la Chapelle
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

6.  Multigene Panel Testing Provides a New Perspective on Lynch Syndrome.

Authors:  Carin R Espenschied; Holly LaDuca; Shuwei Li; Rachel McFarland; Chia-Ling Gau; Heather Hampel
Journal:  J Clin Oncol       Date:  2017-05-17       Impact factor: 44.544

Review 7.  Application of molecular diagnostics for the detection of Lynch syndrome.

Authors:  Maria S Pino; Daniel C Chung
Journal:  Expert Rev Mol Diagn       Date:  2010-07       Impact factor: 5.225

8.  An American founder mutation in MLH1.

Authors:  Jerneja Tomsic; Sandya Liyanarachchi; Heather Hampel; Monika Morak; Brittany C Thomas; Victoria M Raymond; Anu Chittenden; Hans K Schackert; Stephen B Gruber; Sapna Syngal; Alessandra Viel; Elke Holinski-Feder; Stephen N Thibodeau; Albert de la Chapelle
Journal:  Int J Cancer       Date:  2011-08-30       Impact factor: 7.396

9.  Major contribution from recurrent alterations and MSH6 mutations in the Danish Lynch syndrome population.

Authors:  Mef Nilbert; Friedrik P Wikman; Thomas V O Hansen; Henrik B Krarup; Torben F Orntoft; Finn C Nielsen; Lone Sunde; Anne-Marie Gerdes; Dorthe Cruger; Susanne Timshel; Marie-Louise Bisgaard; Inge Bernstein; Henrik Okkels
Journal:  Fam Cancer       Date:  2008-06-20       Impact factor: 2.375

10.  Unstable DNA repair genes shaped by their own sequence modifying phenotypes.

Authors:  Daniel S Falster; Sigve Nakken; Marie Bergem-Ohr; Einar Andreas Rødland; Jarle Breivik
Journal:  J Mol Evol       Date:  2010-03-06       Impact factor: 2.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.